Graig Suvannavejh
Stock Analyst at Mizuho
(3.52)
# 912
Out of 5,017 analysts
164
Total ratings
47.15%
Success rate
6.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $50 → $35 | $26.29 | +33.13% | 19 | Sep 25, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $43 → $44 | $27.03 | +62.78% | 2 | Sep 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $2 → $4 | $2.53 | +58.42% | 9 | Sep 12, 2025 | |
| KALA KALA BIO | Initiates: Outperform | $30 | $1.47 | +1,947.78% | 1 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Outperform | $130 → $165 | $165.87 | -0.52% | 11 | Aug 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $21 → $22 | $24.94 | -11.79% | 10 | Aug 4, 2025 | |
| ALEC Alector | Upgrades: Outperform | $2.5 → $3.5 | $2.95 | +18.64% | 5 | Jul 28, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Outperform | $4 → $5 | $1.85 | +170.27% | 2 | Jul 16, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $4.59 | +161.44% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.19 | +160.42% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $6.12 | +63.40% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $7.27 | +51.31% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $13.34 | +94.98% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.04 | -43.02% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.94 | +0.18% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $120.38 | +79.44% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.68 | +353.73% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $16.50 | +348.48% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $5 | $3.64 | +37.36% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $65.33 | -25.00% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $10.27 | +55.79% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $8.28 | +20.77% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $4.72 | -78.79% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $101.27 | -65.44% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $11.77 | -32.03% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $60.99 | -6.54% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $34.03 | -85.31% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $10.50 | +223.81% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $6.51 | +330.11% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $15.04 | +106.12% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $32.88 | +1,055.72% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.01 | +136.32% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $20.48 | +75.78% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $34.18 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.27 | +2,824.90% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $134.39 | -4.75% | 1 | Sep 14, 2020 |
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Outperform
Price Target: $50 → $35
Current: $26.29
Upside: +33.13%
IDEAYA Biosciences
Sep 12, 2025
Maintains: Outperform
Price Target: $43 → $44
Current: $27.03
Upside: +62.78%
BioXcel Therapeutics
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $2.53
Upside: +58.42%
KALA BIO
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $1.47
Upside: +1,947.78%
Insmed
Aug 13, 2025
Maintains: Outperform
Price Target: $130 → $165
Current: $165.87
Upside: -0.52%
Apellis Pharmaceuticals
Aug 4, 2025
Maintains: Neutral
Price Target: $21 → $22
Current: $24.94
Upside: -11.79%
Alector
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.95
Upside: +18.64%
Neumora Therapeutics
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.85
Upside: +170.27%
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $4.59
Upside: +161.44%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.19
Upside: +160.42%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $6.12
Upside: +63.40%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $7.27
Upside: +51.31%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $13.34
Upside: +94.98%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.04
Upside: -43.02%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.94
Upside: +0.18%
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $120.38
Upside: +79.44%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.68
Upside: +353.73%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $16.50
Upside: +348.48%
Sep 19, 2024
Downgrades: Neutral
Price Target: $50 → $5
Current: $3.64
Upside: +37.36%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $65.33
Upside: -25.00%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $10.27
Upside: +55.79%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $8.28
Upside: +20.77%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $4.72
Upside: -78.79%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $101.27
Upside: -65.44%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $11.77
Upside: -32.03%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $60.99
Upside: -6.54%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $34.03
Upside: -85.31%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $10.50
Upside: +223.81%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $6.51
Upside: +330.11%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $15.04
Upside: +106.12%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $32.88
Upside: +1,055.72%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.01
Upside: +136.32%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $20.48
Upside: +75.78%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $34.18
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.27
Upside: +2,824.90%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $134.39
Upside: -4.75%